最近,美国临床肿瘤学会/美国病理学家学院(ASCO/CAP)更新了浸润性乳腺癌HER2检测指南.对指南更新的影响知之甚少。我们旨在研究2018年ASCO/CAPHER2测试指南更新的影响。我们比较了2013年和2018年ASCO/CAP指南在331例浸润性乳腺癌中解释的HER2FISH结果。我们还分析了这些病例的病理特征和临床结果。与2013年ASCO/CAP指南相比,HER2转阴率从62.5%显著上升至75.8%(P<0.05),根据2018年的指导方针,13.3%从模棱两可变为负面。我们的发现表明,指南更新显着增加了阴性结果的比率。2018年指南对模棱两可的结果进行重新分类是这种变化的主要原因。与阴性结果相比,HER2结果不明确的患者与更大的肿瘤大小和更高的Ki67指数相关。而两者的临床结局相似。
Recently, the American Society of Clinical Oncology/College of American Pathologists (ASCO/CAP) updated the
guidelines on HER2 testing for invasive breast cancer. Little is known about the impact of the
guidelines update. We aimed to study the impact of the 2018 ASCO/CAP HER2 testing
guidelines update. We compared the HER2 FISH results interpreted by 2013 and 2018 ASCO/CAP guidelines in 331 cases of invasive breast cancers. We also analyzed the pathological features and clinical outcomes of these cases. In comparing to the 2013 ASCO/CAP
guidelines, the HER2 negative rate was increased significantly from 62.5% to 75.8%(P < 0.05), and 13.3% changed from equivocal to negative by the 2018
guidelines. Our findings indicate that the guidelines update significantly increased the rate of negative results. The reclassification of the equivocal results by the 2018 guidelines is the main reason for this change. Patients with HER2 equivocal results were associated with larger tumor size and higher Ki67 index than those with negative results, while clinical outcomes were similar between them.